Details
 

August 13-19, 2020

National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat)

Hosted by Epizyme

WEBINAR - Multiple Broadcast Times

Learn more about a new treatment option for your relapsed or refractory follicular lymphoma (FL) patients

In this Live Broadcast, Dr. Pagel, Dr. Burke, and Dr. Kurtin will:

  • Review the Prescribing Information for this new treatment available for relapsed or refractory FL patients
  • Present clinical safety and efficacy data in this patient population
  • Provide important dosing and patient counseling information
  • Discuss a hypothetical patient case study
 
 
 

Printer-Friendly Version


2020-08-13 17:00:00 2020-08-19 21:00:00 America/Detroit National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Learn more about a new treatment option for your relapsed or refractory follicular lymphoma (FL) patients In this Live Broadcast, Dr. Pagel, Dr. Burke, and Dr. Kurtin will: Review the Prescribing Information for this new treatment available for relapsed or refractory FL patients Present clinical safety and efficacy data in this patient population Provide important dosing and patient counseling information Discuss a hypothetical patient case study Click here to register   View the flier       WEBINAR - Multiple Broadcast Times